Amit Tiwari
Concepts (370)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 21 | 2025 | 1216 | 5.330 |
Why?
| | Neoplasms | 20 | 2025 | 1314 | 3.480 |
Why?
| | Apoptosis | 12 | 2025 | 1120 | 2.950 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2025 | 336 | 2.870 |
Why?
| | Drug Delivery Systems | 12 | 2025 | 148 | 2.110 |
Why?
| | Flavonoids | 5 | 2021 | 55 | 2.090 |
Why?
| | Glucosides | 2 | 2025 | 21 | 1.860 |
Why?
| | Pinocytosis | 2 | 2025 | 5 | 1.850 |
Why?
| | Benzhydryl Compounds | 2 | 2025 | 70 | 1.780 |
Why?
| | Skin Absorption | 2 | 2023 | 24 | 1.420 |
Why?
| | Prostatic Neoplasms | 3 | 2025 | 398 | 1.420 |
Why?
| | Sarcoma, Avian | 3 | 2021 | 10 | 1.360 |
Why?
| | Rous sarcoma virus | 3 | 2021 | 4 | 1.360 |
Why?
| | Animals | 34 | 2025 | 13485 | 1.330 |
Why?
| | Depression | 2 | 2025 | 603 | 1.300 |
Why?
| | Oxidative Stress | 4 | 2021 | 805 | 1.260 |
Why?
| | Cell Proliferation | 7 | 2025 | 1013 | 1.260 |
Why?
| | Humans | 75 | 2025 | 52441 | 1.250 |
Why?
| | Mitosis | 2 | 2021 | 87 | 1.210 |
Why?
| | Cocaine | 2 | 2019 | 168 | 1.090 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2025 | 35 | 1.090 |
Why?
| | Colorectal Neoplasms | 3 | 2025 | 286 | 1.070 |
Why?
| | Folic Acid | 2 | 2020 | 137 | 0.950 |
Why?
| | Glutamic Acid | 2 | 2025 | 111 | 0.940 |
Why?
| | Macromolecular Substances | 1 | 2025 | 37 | 0.940 |
Why?
| | Cell Line, Tumor | 11 | 2025 | 1429 | 0.920 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2025 | 51 | 0.920 |
Why?
| | Central Nervous System Neoplasms | 1 | 2025 | 69 | 0.890 |
Why?
| | Endocytosis | 1 | 2025 | 52 | 0.890 |
Why?
| | Lysosomes | 2 | 2024 | 65 | 0.880 |
Why?
| | NF-kappa B | 2 | 2025 | 326 | 0.880 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2023 | 208 | 0.840 |
Why?
| | Arthrogryposis | 1 | 2023 | 5 | 0.830 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 415 | 0.820 |
Why?
| | Haloperidol | 1 | 2023 | 46 | 0.810 |
Why?
| | Hepatitis B | 1 | 2023 | 15 | 0.810 |
Why?
| | Colonic Neoplasms | 2 | 2023 | 163 | 0.810 |
Why?
| | Toxicity Tests | 2 | 2021 | 57 | 0.790 |
Why?
| | Indoles | 1 | 2025 | 283 | 0.780 |
Why?
| | Polyphenols | 3 | 2019 | 40 | 0.780 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2022 | 6 | 0.780 |
Why?
| | Liver Neoplasms | 2 | 2023 | 341 | 0.770 |
Why?
| | Skin | 6 | 2022 | 416 | 0.760 |
Why?
| | Nanoparticles | 8 | 2025 | 131 | 0.760 |
Why?
| | Heterocyclic Compounds | 1 | 2022 | 29 | 0.750 |
Why?
| | Hepatitis C | 1 | 2023 | 80 | 0.750 |
Why?
| | Chickens | 3 | 2021 | 107 | 0.730 |
Why?
| | Chalcones | 1 | 2021 | 1 | 0.720 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 9 | 0.720 |
Why?
| | Neoplasm Metastasis | 3 | 2021 | 235 | 0.710 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 83 | 0.700 |
Why?
| | Endosomes | 1 | 2021 | 34 | 0.700 |
Why?
| | Melanoma | 5 | 2022 | 272 | 0.690 |
Why?
| | Chemoprevention | 2 | 2017 | 19 | 0.680 |
Why?
| | Iron | 2 | 2023 | 123 | 0.670 |
Why?
| | Dietary Supplements | 2 | 2017 | 470 | 0.670 |
Why?
| | Allyl Compounds | 1 | 2020 | 11 | 0.670 |
Why?
| | Hydrazones | 1 | 2020 | 6 | 0.660 |
Why?
| | HCT116 Cells | 3 | 2025 | 31 | 0.650 |
Why?
| | Cytokines | 2 | 2024 | 622 | 0.640 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2025 | 393 | 0.640 |
Why?
| | Biomedical Research | 1 | 2023 | 260 | 0.640 |
Why?
| | Cosmetics | 1 | 2020 | 4 | 0.640 |
Why?
| | Haptophyta | 1 | 2020 | 5 | 0.640 |
Why?
| | Organic Chemicals | 1 | 2020 | 15 | 0.640 |
Why?
| | Healthcare Disparities | 1 | 2023 | 291 | 0.640 |
Why?
| | Disease Models, Animal | 2 | 2025 | 1483 | 0.640 |
Why?
| | Nucleus Accumbens | 2 | 2022 | 26 | 0.620 |
Why?
| | Piperazines | 1 | 2020 | 125 | 0.610 |
Why?
| | Iontophoresis | 1 | 2019 | 13 | 0.600 |
Why?
| | Th2 Cells | 1 | 2019 | 21 | 0.600 |
Why?
| | Ultrasonics | 1 | 2019 | 25 | 0.590 |
Why?
| | Th1 Cells | 1 | 2019 | 51 | 0.580 |
Why?
| | Major Histocompatibility Complex | 1 | 2018 | 13 | 0.580 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2018 | 18 | 0.570 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2021 | 299 | 0.570 |
Why?
| | Alzheimer Disease | 1 | 2022 | 356 | 0.560 |
Why?
| | Quinolines | 1 | 2018 | 44 | 0.560 |
Why?
| | Prefrontal Cortex | 1 | 2018 | 85 | 0.550 |
Why?
| | Liposomes | 5 | 2022 | 53 | 0.550 |
Why?
| | Pyrazoles | 1 | 2018 | 116 | 0.520 |
Why?
| | Histone Deacetylase Inhibitors | 4 | 2025 | 57 | 0.520 |
Why?
| | Epigenesis, Genetic | 4 | 2025 | 396 | 0.520 |
Why?
| | Alcohol Drinking | 1 | 2018 | 235 | 0.500 |
Why?
| | Pyrimidines | 1 | 2017 | 199 | 0.480 |
Why?
| | Ethanol | 1 | 2018 | 334 | 0.480 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 257 | 0.480 |
Why?
| | Breast Neoplasms | 4 | 2024 | 1203 | 0.440 |
Why?
| | Behavior, Animal | 2 | 2025 | 190 | 0.430 |
Why?
| | Molecular Targeted Therapy | 3 | 2025 | 135 | 0.420 |
Why?
| | Antioxidants | 4 | 2022 | 255 | 0.420 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 1004 | 0.410 |
Why?
| | Eichhornia | 2 | 2022 | 2 | 0.390 |
Why?
| | Drug Discovery | 3 | 2022 | 94 | 0.380 |
Why?
| | Curcumin | 3 | 2021 | 20 | 0.360 |
Why?
| | Female | 14 | 2024 | 28277 | 0.350 |
Why?
| | Iron, Dietary | 1 | 2011 | 8 | 0.350 |
Why?
| | Hematinics | 1 | 2011 | 15 | 0.350 |
Why?
| | Male | 10 | 2025 | 26874 | 0.350 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2011 | 24 | 0.340 |
Why?
| | Signal Transduction | 5 | 2025 | 1724 | 0.340 |
Why?
| | Excipients | 1 | 2010 | 9 | 0.340 |
Why?
| | Mice | 6 | 2025 | 5899 | 0.320 |
Why?
| | Peptides | 1 | 2010 | 239 | 0.310 |
Why?
| | HEK293 Cells | 2 | 2021 | 236 | 0.300 |
Why?
| | Drug Carriers | 3 | 2021 | 68 | 0.290 |
Why?
| | Dogs | 2 | 2025 | 183 | 0.280 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 441 | 0.280 |
Why?
| | Structure-Activity Relationship | 5 | 2023 | 399 | 0.280 |
Why?
| | Proteins | 1 | 2010 | 353 | 0.270 |
Why?
| | Nanotubes, Carbon | 2 | 2022 | 43 | 0.270 |
Why?
| | Administration, Oral | 3 | 2021 | 455 | 0.260 |
Why?
| | Biological Availability | 5 | 2024 | 107 | 0.250 |
Why?
| | RNA, Messenger | 2 | 2020 | 1134 | 0.250 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2025 | 3 | 0.240 |
Why?
| | Doxorubicin | 3 | 2024 | 246 | 0.240 |
Why?
| | Unfolded Protein Response | 1 | 2025 | 35 | 0.240 |
Why?
| | Biomass | 5 | 2022 | 22 | 0.230 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 50 | 0.230 |
Why?
| | Swine | 2 | 2024 | 428 | 0.230 |
Why?
| | Hydrazines | 1 | 2025 | 19 | 0.230 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2025 | 39 | 0.230 |
Why?
| | Paclitaxel | 1 | 2025 | 91 | 0.230 |
Why?
| | Skin Neoplasms | 2 | 2021 | 496 | 0.230 |
Why?
| | Lipids | 3 | 2021 | 163 | 0.220 |
Why?
| | Limonins | 1 | 2024 | 1 | 0.220 |
Why?
| | Movement Disorders | 1 | 2024 | 16 | 0.210 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2021 | 178 | 0.210 |
Why?
| | Lipopolysaccharides | 1 | 2025 | 205 | 0.210 |
Why?
| | Brain Neoplasms | 2 | 2025 | 302 | 0.210 |
Why?
| | Acute Pain | 1 | 2024 | 12 | 0.210 |
Why?
| | Hydrops Fetalis | 1 | 2023 | 2 | 0.210 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2024 | 83 | 0.210 |
Why?
| | Kinetics | 5 | 2022 | 613 | 0.210 |
Why?
| | Eye | 1 | 2024 | 28 | 0.210 |
Why?
| | Phenotype | 2 | 2023 | 792 | 0.210 |
Why?
| | Capsaicin | 1 | 2023 | 18 | 0.210 |
Why?
| | Lorazepam | 1 | 2023 | 13 | 0.210 |
Why?
| | Cyclosporine | 1 | 2024 | 65 | 0.210 |
Why?
| | Diphenhydramine | 1 | 2023 | 19 | 0.210 |
Why?
| | Trypanosoma | 1 | 2023 | 1 | 0.210 |
Why?
| | Trypanosomiasis | 1 | 2023 | 1 | 0.210 |
Why?
| | Toll-Like Receptor 5 | 1 | 2023 | 5 | 0.200 |
Why?
| | Retinal Diseases | 1 | 2024 | 53 | 0.200 |
Why?
| | Cell Survival | 2 | 2024 | 598 | 0.200 |
Why?
| | Neoplasm Proteins | 1 | 2025 | 328 | 0.200 |
Why?
| | Cholestasis | 1 | 2023 | 41 | 0.200 |
Why?
| | Stress, Psychological | 1 | 2025 | 275 | 0.200 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2022 | 7 | 0.200 |
Why?
| | Silicon Dioxide | 1 | 2022 | 12 | 0.200 |
Why?
| | Cyclodextrins | 1 | 2022 | 16 | 0.200 |
Why?
| | Colitis | 1 | 2023 | 49 | 0.200 |
Why?
| | Analgesics | 1 | 2024 | 106 | 0.190 |
Why?
| | Administration, Cutaneous | 2 | 2022 | 53 | 0.190 |
Why?
| | Glioblastoma | 1 | 2024 | 89 | 0.190 |
Why?
| | Fetus | 1 | 2023 | 191 | 0.190 |
Why?
| | Climate Change | 1 | 2023 | 56 | 0.190 |
Why?
| | Biofuels | 1 | 2022 | 6 | 0.190 |
Why?
| | Treatment Outcome | 2 | 2023 | 5508 | 0.190 |
Why?
| | Holography | 1 | 2022 | 1 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 186 | 0.190 |
Why?
| | Nitrogen | 1 | 2022 | 70 | 0.190 |
Why?
| | Oncolytic Viruses | 1 | 2022 | 12 | 0.180 |
Why?
| | Oncolytic Virotherapy | 1 | 2022 | 19 | 0.180 |
Why?
| | Aegle | 1 | 2021 | 1 | 0.180 |
Why?
| | Patents as Topic | 1 | 2022 | 10 | 0.180 |
Why?
| | Eye Infections | 1 | 2021 | 5 | 0.180 |
Why?
| | Keratitis | 1 | 2021 | 12 | 0.180 |
Why?
| | Medical Oncology | 1 | 2022 | 97 | 0.180 |
Why?
| | Delayed-Action Preparations | 3 | 2024 | 57 | 0.180 |
Why?
| | HT29 Cells | 1 | 2021 | 14 | 0.180 |
Why?
| | Patient Care | 1 | 2022 | 58 | 0.180 |
Why?
| | Cathepsins | 1 | 2021 | 7 | 0.180 |
Why?
| | Environmental Pollutants | 1 | 2022 | 104 | 0.180 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2021 | 43 | 0.180 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2021 | 7 | 0.180 |
Why?
| | Phosphatidylcholines | 1 | 2021 | 27 | 0.180 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 19 | 0.180 |
Why?
| | Cricetulus | 1 | 2021 | 100 | 0.170 |
Why?
| | CHO Cells | 1 | 2021 | 123 | 0.170 |
Why?
| | Water Purification | 1 | 2021 | 10 | 0.170 |
Why?
| | Biological Transport | 1 | 2021 | 153 | 0.170 |
Why?
| | Catechols | 1 | 2020 | 7 | 0.170 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 93 | 0.170 |
Why?
| | Muscle Proteins | 1 | 2023 | 343 | 0.170 |
Why?
| | HeLa Cells | 1 | 2021 | 243 | 0.170 |
Why?
| | Drug Stability | 3 | 2021 | 38 | 0.170 |
Why?
| | Zebrafish | 1 | 2021 | 61 | 0.170 |
Why?
| | Water Pollutants, Chemical | 1 | 2021 | 54 | 0.170 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2018 | 135 | 0.170 |
Why?
| | Lead | 1 | 2020 | 32 | 0.170 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2020 | 12 | 0.170 |
Why?
| | Prospective Studies | 2 | 2020 | 2433 | 0.170 |
Why?
| | Drug Resistance | 1 | 2020 | 69 | 0.170 |
Why?
| | Amides | 1 | 2020 | 36 | 0.160 |
Why?
| | Water Loss, Insensible | 1 | 2020 | 1 | 0.160 |
Why?
| | Acyclovir | 1 | 2020 | 9 | 0.160 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 206 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2022 | 124 | 0.160 |
Why?
| | Anemia | 1 | 2020 | 75 | 0.160 |
Why?
| | Prevalence | 1 | 2023 | 1016 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 124 | 0.160 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 1888 | 0.160 |
Why?
| | Drug Design | 1 | 2020 | 122 | 0.160 |
Why?
| | Chemokines | 1 | 2019 | 77 | 0.160 |
Why?
| | Lidocaine | 1 | 2020 | 48 | 0.160 |
Why?
| | Autophagy | 1 | 2021 | 185 | 0.150 |
Why?
| | Ceramides | 1 | 2019 | 33 | 0.150 |
Why?
| | Protein Binding | 1 | 2021 | 673 | 0.150 |
Why?
| | Pandemics | 2 | 2022 | 580 | 0.150 |
Why?
| | Cell Cycle | 1 | 2020 | 236 | 0.150 |
Why?
| | Cell Movement | 1 | 2020 | 271 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 231 | 0.150 |
Why?
| | Drug Resistance, Multiple | 1 | 2019 | 25 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1020 | 0.150 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 158 | 0.150 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2020 | 333 | 0.150 |
Why?
| | Cell Line | 1 | 2021 | 1020 | 0.150 |
Why?
| | Dipeptides | 1 | 2018 | 21 | 0.140 |
Why?
| | Thermogravimetry | 3 | 2022 | 7 | 0.140 |
Why?
| | Inflammation Mediators | 1 | 2019 | 113 | 0.140 |
Why?
| | Haplotypes | 1 | 2018 | 95 | 0.140 |
Why?
| | Lignans | 1 | 2017 | 7 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 130 | 0.130 |
Why?
| | Hydroxybenzoates | 1 | 2017 | 24 | 0.130 |
Why?
| | Cell Nucleus | 1 | 2018 | 189 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 175 | 0.130 |
Why?
| | Pregnancy | 2 | 2023 | 2642 | 0.130 |
Why?
| | Up-Regulation | 1 | 2019 | 462 | 0.130 |
Why?
| | Stilbenes | 1 | 2017 | 58 | 0.130 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 56 | 0.130 |
Why?
| | Substance-Related Disorders | 1 | 2022 | 615 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.130 |
Why?
| | Young Adult | 2 | 2020 | 4346 | 0.130 |
Why?
| | Molecular Structure | 1 | 2017 | 317 | 0.130 |
Why?
| | Gene Expression | 1 | 2019 | 618 | 0.120 |
Why?
| | Particle Size | 3 | 2021 | 76 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 1 | 2020 | 1558 | 0.120 |
Why?
| | Solubility | 3 | 2021 | 81 | 0.120 |
Why?
| | Obesity | 1 | 2023 | 1176 | 0.110 |
Why?
| | Adult | 4 | 2023 | 14205 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1365 | 0.110 |
Why?
| | Pharmaceutical Preparations | 2 | 2024 | 73 | 0.100 |
Why?
| | Rats | 1 | 2018 | 3228 | 0.090 |
Why?
| | Lipid Bilayers | 2 | 2022 | 12 | 0.090 |
Why?
| | Brain | 1 | 2019 | 1337 | 0.090 |
Why?
| | Polymers | 2 | 2023 | 51 | 0.090 |
Why?
| | Polyethylene Glycols | 2 | 2022 | 93 | 0.090 |
Why?
| | Drug Compounding | 2 | 2021 | 26 | 0.090 |
Why?
| | Drug Storage | 1 | 2010 | 2 | 0.090 |
Why?
| | Dendrimers | 1 | 2010 | 2 | 0.090 |
Why?
| | Microspheres | 1 | 2010 | 20 | 0.080 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2010 | 35 | 0.080 |
Why?
| | Superoxide Dismutase | 1 | 2011 | 120 | 0.080 |
Why?
| | DNA Methylation | 2 | 2025 | 573 | 0.080 |
Why?
| | Immunotherapy | 2 | 2023 | 251 | 0.080 |
Why?
| | Glutathione | 1 | 2011 | 301 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2011 | 558 | 0.080 |
Why?
| | Inflammation | 2 | 2024 | 649 | 0.080 |
Why?
| | Prognosis | 2 | 2024 | 2100 | 0.070 |
Why?
| | Multiple Myeloma | 1 | 2021 | 3013 | 0.060 |
Why?
| | Platinum Compounds | 1 | 2025 | 10 | 0.060 |
Why?
| | Nanomedicine | 1 | 2025 | 15 | 0.060 |
Why?
| | Copper | 1 | 2025 | 47 | 0.060 |
Why?
| | Drug Synergism | 1 | 2025 | 147 | 0.060 |
Why?
| | Administration, Ophthalmic | 1 | 2024 | 4 | 0.050 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 19 | 0.050 |
Why?
| | Nanotechnology | 1 | 2024 | 31 | 0.050 |
Why?
| | Dopaminergic Neurons | 1 | 2024 | 19 | 0.050 |
Why?
| | Methyltransferases | 1 | 2024 | 26 | 0.050 |
Why?
| | Emulsions | 1 | 2024 | 25 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 71 | 0.050 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 86 | 0.050 |
Why?
| | Anthracyclines | 1 | 2024 | 34 | 0.050 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2024 | 56 | 0.050 |
Why?
| | Homozygote | 1 | 2023 | 58 | 0.050 |
Why?
| | Succinic Acid | 1 | 2023 | 3 | 0.050 |
Why?
| | Dextran Sulfate | 1 | 2023 | 8 | 0.050 |
Why?
| | Zinc | 1 | 2024 | 57 | 0.050 |
Why?
| | Droughts | 1 | 2023 | 13 | 0.050 |
Why?
| | India | 1 | 2023 | 60 | 0.050 |
Why?
| | Agriculture | 1 | 2023 | 18 | 0.050 |
Why?
| | Inulin | 1 | 2023 | 11 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 71 | 0.050 |
Why?
| | Antigens, Protozoan | 1 | 2023 | 13 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2024 | 176 | 0.050 |
Why?
| | Horses | 1 | 2023 | 49 | 0.050 |
Why?
| | Patient Selection | 1 | 2025 | 269 | 0.050 |
Why?
| | Computational Biology | 1 | 2025 | 209 | 0.050 |
Why?
| | Deuterium | 1 | 2023 | 47 | 0.050 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2022 | 2 | 0.050 |
Why?
| | Glutamates | 1 | 2022 | 22 | 0.050 |
Why?
| | Cardiolipins | 1 | 2022 | 1 | 0.050 |
Why?
| | beta-Lactams | 1 | 2022 | 32 | 0.050 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2022 | 24 | 0.050 |
Why?
| | Porosity | 1 | 2022 | 32 | 0.050 |
Why?
| | Daunorubicin | 1 | 2022 | 13 | 0.050 |
Why?
| | Bile Acids and Salts | 1 | 2023 | 81 | 0.050 |
Why?
| | Phosphorylcholine | 1 | 2022 | 19 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2022 | 63 | 0.050 |
Why?
| | Anaerobiosis | 1 | 2022 | 21 | 0.050 |
Why?
| | Phylogeny | 1 | 2023 | 229 | 0.050 |
Why?
| | Methane | 1 | 2022 | 10 | 0.050 |
Why?
| | Silver | 1 | 2022 | 48 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2023 | 187 | 0.050 |
Why?
| | Digestion | 1 | 2022 | 29 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 205 | 0.050 |
Why?
| | Lecithins | 1 | 2022 | 1 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2022 | 95 | 0.050 |
Why?
| | Phenylethyl Alcohol | 1 | 2022 | 5 | 0.050 |
Why?
| | Genetic Variation | 1 | 2023 | 226 | 0.050 |
Why?
| | Surface-Active Agents | 1 | 2022 | 10 | 0.050 |
Why?
| | Solid Waste | 1 | 2021 | 2 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 248 | 0.050 |
Why?
| | Chemokine CCL5 | 1 | 2021 | 9 | 0.050 |
Why?
| | RNA, Viral | 1 | 2022 | 123 | 0.050 |
Why?
| | Cholesterol | 1 | 2022 | 159 | 0.050 |
Why?
| | Mammals | 1 | 2022 | 59 | 0.050 |
Why?
| | Microscopy | 1 | 2022 | 47 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 63 | 0.050 |
Why?
| | Cadaver | 1 | 2022 | 88 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 641 | 0.040 |
Why?
| | Histones | 1 | 2023 | 315 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 1 | 2021 | 50 | 0.040 |
Why?
| | Adenosine | 1 | 2022 | 75 | 0.040 |
Why?
| | Snakes | 1 | 2021 | 1 | 0.040 |
Why?
| | Necrosis | 1 | 2022 | 169 | 0.040 |
Why?
| | RNA | 1 | 2022 | 174 | 0.040 |
Why?
| | Gallbladder Neoplasms | 1 | 2021 | 7 | 0.040 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 5 | 0.040 |
Why?
| | Transcription Factor RelA | 1 | 2021 | 32 | 0.040 |
Why?
| | Cholecystitis | 1 | 2021 | 11 | 0.040 |
Why?
| | Adsorption | 1 | 2021 | 18 | 0.040 |
Why?
| | Cell Death | 1 | 2022 | 169 | 0.040 |
Why?
| | Permeability | 1 | 2021 | 69 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2022 | 189 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 609 | 0.040 |
Why?
| | Amino Acids | 1 | 2023 | 386 | 0.040 |
Why?
| | Half-Life | 1 | 2021 | 86 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2021 | 109 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 97 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 136 | 0.040 |
Why?
| | Fruit | 1 | 2021 | 130 | 0.040 |
Why?
| | Click Chemistry | 1 | 2020 | 3 | 0.040 |
Why?
| | Carbamates | 1 | 2020 | 15 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 218 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2023 | 903 | 0.040 |
Why?
| | Urea | 1 | 2020 | 80 | 0.040 |
Why?
| | Limit of Detection | 1 | 2020 | 21 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 224 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 185 | 0.040 |
Why?
| | Triazoles | 1 | 2020 | 115 | 0.040 |
Why?
| | Quercetin | 1 | 2019 | 17 | 0.040 |
Why?
| | Catechin | 1 | 2019 | 15 | 0.040 |
Why?
| | Epidermis | 1 | 2019 | 32 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 354 | 0.040 |
Why?
| | Calorimetry, Differential Scanning | 1 | 2019 | 8 | 0.040 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2019 | 43 | 0.040 |
Why?
| | Pyridines | 1 | 2020 | 137 | 0.040 |
Why?
| | Linear Models | 1 | 2020 | 288 | 0.040 |
Why?
| | Xenorhabdus | 1 | 2018 | 1 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2018 | 20 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 175 | 0.040 |
Why?
| | Mutation | 1 | 2024 | 1331 | 0.040 |
Why?
| | Cell Membrane | 1 | 2019 | 238 | 0.040 |
Why?
| | Stereoisomerism | 1 | 2018 | 100 | 0.040 |
Why?
| | Middle Aged | 2 | 2023 | 13133 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 816 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 1223 | 0.030 |
Why?
| | Aged | 1 | 2021 | 10242 | 0.020 |
Why?
|
|
Tiwari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|